Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy

Therapeutic Advances in Neurological Disorders

Volumn 4, Issue 3, 2011, Pages 193-200

  Yoon, Min Suk ^a   Chan, Andrew ^a   Gold, Ralf ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

chronic inflammatory demyelinating polyradiculoneuropathy; immunosuppression; monoclonal antibodies

Indexed keywords

AZATHIOPRINE; CARBAMAZEPINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FOLIC ACID; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL CONTRACEPTIVE AGENT; PLACEBO; PREDNISONE; RITUXIMAB;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEVER; HORMONE RECEPTOR INTERACTION; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROLOGICAL COMPLICATION; NEUTROPENIA; PLASMAPHERESIS; PRIORITY JOURNAL;

EID: 79956124803     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285611405564     Document Type: Review

References (61)

1. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force (1991) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 41: 617–618.
2. Barnett M.H. Pollard J.D. Davies L. McLeod J.G. (1998) Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 21: 454–460.
3. Barohn R.J. Kissel J.T. Warmolts J.R. Mendell J.R. (1989) Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 46: 878–884.
4. Benedetti L. Briani C. Franciotta D. Fazio R. Paolasso I. Comi C. et al (2011) Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 82 (3): 306–308.
5. Benedetti L. Franciotta D. Beronio A. Cadenotti L. Gobbi M. Mancardi G.L. et al (2008) Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura. Muscle Nerve 38: 1076–1077.
6. Berger M. Cupps T.R. Fauci A.S. (1980) Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 93: 55–56.
7. Berger M. Cupps T.R. Fauci A.S. (1982) High-dose immunoglobulin replacement therapy by slow subcutaneous infusion during pregnancy. JAMA 247: 2824–2825.
8. Blume G. Pestronk A. Goodnough L.T. (1995) Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology 45: 1577–1580.
9. Brannagan T.H. III Pradhan A. Heiman-Patterson T. Winkelman A.C. Styler M.J. Topolsky D.L. et al (2002) High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 58: 1856–1858.
10. Brecher M.E. (2002) Plasma exchange: why we do what we do. J Clin Apher 17: 207–211.
11. Chaudhry V. Cornblath D.R. Griffin J.W. O'Brien R. Drachman D.B. (2001) Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 56: 94–96.
12. Dalakas M.C. (2004) The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 102: 177–193.
13. Dalakas M.C. Engel W.K. (1981) Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 9(Suppl.): 134–145.
14. Dalakas M.C. Rakocevic G. Salajegheh M. Dambrosia J.M. Hahn A.F. Raju R. et al (2009) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 65: 286–293.
15. Dyck P.J. Daube J. O'Brien P. Pineda A. Low P.A. Windebank A.J. et al (1986) Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314: 461–465.
16. Dyck P.J. Lais A.C. Ohta M. Bastron J.A. Okazaki H. Groover R.V. (1975) Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50: 621–637.
17. Dyck P.J. Litchy W.J. Kratz K.M. Suarez G.A. Low P.A. Pineda A.A. et al (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36: 838–845.
18. Dyck P.J. O'Brien P. Swanson C. Low P. Daube J. (1985) Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 35: 1173–1176.
19. Dyck P.J. O'Brien P.C. Oviatt K.F. Dinapoli R.P. Daube J.R. Bartleson J.D. et al (1982) Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11: 136–141.
20. Garside H. Stevens A. Farrow S. Normand C. Houle B. Berry A. et al (2004) Glucocorticoid ligands specify different interactions with NF-kappaB by allosteric effects on the glucocorticoid receptor DNA binding domain. J Biol Chem 279: 50050–50059.
21. Gladstone D.E. Golightly M.G. Brannagan T.H. III (2007) High dose cyclophosphamide preferentially targets naive T (CD45/CD4/RA+) cells in CIDP and MS patients. J Neuroimmunol 190: 121–126.
22. Gladstone D.E. Prestrud A.A. Brannagan T.H. III (2005) High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 10: 11–16.
23. Gold R. Schneider-Gold C. (2008) Current and future standards in treatment of myasthenia gravis. Neurotherapeutics 5: 535–541.
24. Gold R. Stangel M. Dalakas M.C. (2007) Drug Insight: the use of intravenous immunoglobulin in neurology–therapeutic considerations and practical issues. Nat Clin Pract Neurol 3: 36–44.
25. Good J.L. Chehrenama M. Mayer R.F. Koski C.L. (1998) Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 51: 1735–1738.
26. Gorson K.C. Amato A.A. Ropper A.H. (2004) Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 63: 715–717.
27. Gorson K.C. Ropper A.H. (2003) Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): a review of clinical syndromes and treatment approaches in clinical practice. J Clin Neuromuscul Dis 4: 174–189.
28. Grillo-Lopez A.J. Hedrick E. Rashford M. Benyunes M. (2002) Rituximab: ongoing and future clinical development. Semin Oncol 29(1 Suppl. 2): 105–112.
29. Hahn A.F. (1998) Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Neurology 51(6 Suppl. 5): S16–S21.
30. Hahn A.F. Bolton C.F. Pillay N. Chalk C. Benstead T. Bril V. et al (1996) Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119: 1055–1066.
31. Hauser S.L. Waubant E. Arnold D.L. Vollmer T. Antel J. Fox R.J. et al (2008) B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 358: 676–688.
32. Hughes R. Bensa S. Willison H. van den Bergh P. Comi G. Illa I. et al (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50: 195–201.
33. Hughes R.A. Donofrio P. Bril V. Dalakas M.C. Deng C. Hanna K. et al (2008) Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7: 136–144.
34. Koller H. Kieseier B.C. Jander S. Hartung H.P. (2005) Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352: 1343–1356.
35. Kuitwaard K. van Doorn P.A. (2009) Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy. Drugs 69: 987–1001.
36. Leahy M.F. (1986) Subcutaneous immunoglobulin home treatment in hypogammaglobulinaemia. Lancet 2: 48–49.
37. Lee D.H. Linker R.A. Paulus W. Schneider-Gold C. Chan A. Gold R. (2008) Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 37: 406–409.
38. Levine T.D. Pestronk A. (1999) IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 52: 1701–1704.
39. Lopate G. Pestronk A. Al-Lozi M. (2005) Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 62: 249–254.
40. Mahattanakul W. Crawford T.O. Griffin J.W. Goldstein J.M. Cornblath D.R. (1996) Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J Neurol Neurosurg Psychiatry 60: 185–187.
41. Matsuda M. Hoshi K. Gono T. Morita H. Ikeda S. (2004) Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 224: 29–35.
42. McCombe P.A. Pollard J.D. McLeod J.G. (1987) Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 110: 1617–1630.
43. Mehndiratta M.M. Hughes R.A. (2002) Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 1: CD002062–CD002062.
44. Merkies I.S. Bril V. Dalakas M.C. Deng C. Donofrio P. Hanna K. et al (2009) Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study. Neurology 72: 1337–1344.
45. Molenaar D.S. van Doorn P.A. Vermeulen M. (1997) Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry 62: 388–390.
46. Mowzoon N. Sussman A. Bradley W.G. (2001) Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 185: 119–122.
47. Muley S.A. Kelkar P. Parry G.J. (2008) Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol 65: 1460–1464.
48. Munch C. Anagnostou P. Meyer R. Haas J. (2007) Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurol Sci 256: 100–102.
49. Pedersen-Bjergaard J. Ersboll J. Sorensen H.M. Keiding N. Larsen S.O. Philip P. et al (1985) Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 103: 195–200.
50. Pentland B. Adams G.G. Mawdsley C. (1982) Chronic idiopathic polyneuropathy treated with azathioprine. J Neurol Neurosurg Psychiatry 45: 866–869.
51. Pestronk A. Florence J. Miller T. Choksi R. Al-Lozi M.T. Levine T.D. (2003) Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 74: 485–489.
52. Prineas J.W. McLeod J.G. (1976) Chronic relapsing polyneuritis. J Neurol Sci 27: 427–458.
53. Renaud S. Gregor M. Fuhr P. Lorenz D. Deuschl G. Gratwohl A. et al (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27: 611–615.
54. R.M.C. Trial Group (2009) Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC Trial): a pilot, multicentre study. Lancet Neurol 8: 158–164.
55. Ruts L. Drenthen J. Jacobs B.C. van Doorn P.A. (2010) Distinguishing acute-onset CIDP from fluctuating Guillain–Barre syndrome: a prospective study. Neurology 74: 1680–1686.
56. Sander H.W. Latov N. (2003) Research criteria for defining patients with CIDP. Neurology 60(8 Suppl. 3): S8–S15.
57. Silverman G.J. Weisman S. (2003) Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 48: 1484–1492.
58. Umapathi T. Hughes R. (2002) Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol 9: 683–685.
59. van Schaik I.N. Eftimov F. van Doorn P.A. Brusse E. van den Berg L.H. van der Pol W.L. et al (2010) Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 9: 245–253.
60. Waniewski J. Gardulf A. Hammarstrom L. (1994) Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 14: 90–97.
61. Weinstein R. (2000) Therapeutic apheresis in neurological disorders. J Clin Apher 15: 74–128.